259 related articles for article (PubMed ID: 28028664)
21. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
Kim SY; Yoon MJ; Park YI; Kim MJ; Nam BH; Park SR
Gastric Cancer; 2018 May; 21(3):453-463. PubMed ID: 28828688
[TBL] [Abstract][Full Text] [Related]
22. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Oncology; 2010; 79(5-6):363-9. PubMed ID: 21430405
[TBL] [Abstract][Full Text] [Related]
23. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
24. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Chung IJ
Gastric Cancer; 2011 Aug; 14(3):249-56. PubMed ID: 21431297
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2018 Nov; 38(11):6473-6478. PubMed ID: 30396974
[TBL] [Abstract][Full Text] [Related]
27. Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy.
Stahl M; Müller C; Köster W; Wilke H
Onkologie; 2005 Oct; 28(10):499-502. PubMed ID: 16160395
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
29. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
[TBL] [Abstract][Full Text] [Related]
31. A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and Prognosis in Patients with Advanced Gastric Cancer.
Arigami T; Uenosono Y; Ishigami S; Okubo K; Kijima T; Yanagita S; Okumura H; Uchikado Y; Kijima Y; Nakajo A; Kurahara H; Kita Y; Mori S; Maemura K; Natsugoe S
Oncology; 2016; 90(4):186-92. PubMed ID: 26981856
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
33. Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer.
Inoue D; Sekiguchi S; Yamagata W; Maeda G; Yamada D; Fujiwara S; Itou S; Kurihara M; Hijioka Y; Shimoji K; Fujiki J; Nakazono A; Horike H; Yoshioka A; Ogura Y; Hatao F; Imamura K; Namiki S
Oncology; 2019; 96(3):140-146. PubMed ID: 30368510
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies.
Abdel-Rahman O
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):711-715. PubMed ID: 30897976
[No Abstract] [Full Text] [Related]
35. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
[TBL] [Abstract][Full Text] [Related]
36. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Choi IS; Kim JH; Lee JH; Suh KJ; Lee JY; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(10):e0205853. PubMed ID: 30346970
[TBL] [Abstract][Full Text] [Related]
37. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
38. The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis.
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Sheen SS
Medicine (Baltimore); 2018 Sep; 97(39):e12588. PubMed ID: 30278571
[TBL] [Abstract][Full Text] [Related]
39. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
40. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Catalano V; Graziano F; Santini D; D'Emidio S; Baldelli AM; Rossi D; Vincenzi B; Giordani P; Alessandroni P; Testa E; Tonini G; Catalano G
Br J Cancer; 2008 Nov; 99(9):1402-7. PubMed ID: 18971936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
